Physician samples on job work basis not free distribution, Rule 4 valuation inapplicable, duty on 110% production cost

CESTAT Mumbai held that physician samples manufactured on job work basis and returned to principal manufacturer are not distributed free of cost, making Rule 4 of Central Excise Valuation Rules inapplicable. Following Supreme Court precedent in Ujagar Prints, duty should be based on 110% of production cost. For samples sold to distributors, transaction value under Section 4(1)(a) applies per Sun Pharmaceuticals judgment, not Rule 4 valuation. Revenue's demand for higher duty assessment rejected in both scenarios.

---

---

The core legal questions considered in this judgment revolve around the correct valuation of physician samples for the purpose of central excise duty assessment. Specifically, the issues are:

1. Whether physician samples manufactured and distributed free of cost by the manufacturer should be valued under Rule 4 of the Central Excise Valuation (Determination of Price of Excisable Goods) Rules, 2000, or assessed on the basis of transaction value under Section 4(1)(a) of the Central Excise Act.

2. The appropriate valuation method for physician samples manufactured on a job work basis for another principal manufacturer and subsequently distributed free of cost by the principal manufacturer.

3. The applicability and interpretation of relevant circulars and precedents, including the Board's Circular No. 813/10-2005-CX dated 25/04/2005, and Supreme Court decisions, particularly in relation to whether the valuation rules or transaction value provisions govern the assessment of physician samples.

4. Whether the valuation of physician samples sold by the manufacturer to distributors, who then distribute them free of cost, should be assessed on transaction value or under valuation rules.

5. The correctness of the demand raised by the revenue for differential duty based on valuation under Rule 4, and the reduction of penalty imposed by the Commissioner (Appeals).

Issue-wise Detailed Analysis

Issue 1: Valuation of Physician Samples Distributed Free of Cost by Manufacturer

The legal framework involves the Central Excise Valuation Rules, 2000, particularly Rule 4 and Rule 11, and Section 4(1)(a) of the Central Excise Act, 1944. Rule 4 is the general valuation rule applicable when transaction value is not available, while Section 4(1)(a) provides for transaction value-based assessment when price is available.

The Commissioner (Appeals) and the Tribunal considered the Bombay High Court's observations in a writ petition, which held that valuation of physician samples distributed free of cost should be determined under Rule 11 read with Rule 4, rejecting Rule 8 as inapplicable since physician samples are not for captive consumption but are similar to goods sold in the market.

The Court recognized that when physician samples are distributed free by the manufacturer without any sale transaction, Rule 4 valuation is appropriate. This aligns with the Board Circular No. 813/10-2005-CX, which instructs that samples given free as marketing strategy or gifts should be valued under Rule 4.

Competing arguments from the appellant relied on Supreme Court decisions that emphasize transaction value where price is charged, but these are distinguishable where no sale occurs. The Court upheld the principle that in absence of a sale, valuation under Rule 4 is justified.

The conclusion was that for physician samples distributed free of cost by the manufacturer, Rule 4 valuation applies.

Issue 2: Valuation of Physician Samples Manufactured on Job Work Basis for Principal Manufacturer

The facts showed that the appellant manufactured physician samples on a job work basis for principal manufacturers, who then distributed or sold these samples for free distribution. The question was whether valuation under Rule 4 or transaction value under Section 4(1)(a) applies.

The Court examined precedents including the Larger Bench decision in Cadila Pharmaceuticals Ltd. and the Bombay High Court decision in Indian Drugs Manufacturer's Association. These dealt with physician samples distributed free by the manufacturer themselves and were found inapplicable to job work situations.

The Tribunal relied on the Apex Court's judgment in Ujagar Prints Ltd., which held that valuation in job work cases should be based on cost of raw materials plus job charges and profit, reflecting transaction value principles.

The Court also referred to the Tribunal's decision in Omni Protech Drugs Pvt. Ltd., which held that physician samples cleared by job workers to brand owners on transaction value basis are correctly valued, rejecting valuation under Rule 4.

The Court concluded that where physician samples are manufactured on job work basis and sold to the principal manufacturer, valuation should be on transaction value basis as per Ujagar Prints formula, not under Rule 4. The demand raised on this category was rightly dropped by the Commissioner (Appeals), and the revenue's appeal was dismissed.

Issue 3: Valuation of Physician Samples Manufactured and Sold by Manufacturer to Distributors

Here, the appellant manufactured physician samples for itself and sold them to distributors who distributed them free of cost. The revenue sought to value these samples under Rule 4, while the appellant argued for transaction value under Section 4(1)(a).

The Court relied heavily on the Supreme Court decision in Sun Pharmaceuticals Industries Ltd., where it was held that the transaction between manufacturer and distributor is the relevant transaction for valuation. The fact that distributors give samples free to physicians is extraneous and does not affect the transaction value.

The Supreme Court observed that the show cause notice was founded on a wrong reason by ignoring the transaction value between manufacturer and distributor. The genuineness of the price charged was not doubted, and thus the valuation under Section 4(1)(a) was appropriate.

The Court applied this principle to the instant case, holding that since the appellant sold physician samples to distributors at a genuine price, the transaction value is the assessable value, not a Rule 4 valuation.

The Court allowed the appeal on this issue, setting aside the demand based on Rule 4 valuation.

Issue 4: Applicability of Board Circulars and Precedents

The revenue relied on Board Circular No. 813/10-2005-CX dated 25/04/2005, which directs valuation of free samples under Rule 4. The appellant relied on Supreme Court decisions including Sun Pharmaceuticals Industries Ltd., Medley Pharmaceuticals Ltd., and others.

The Court distinguished the facts of these precedents carefully. It noted that the Circular is applicable primarily where no sale transaction exists and samples are distributed free by the manufacturer. Where a sale transaction exists, the Circular does not override the statutory provision of Section 4(1)(a).

The Court also examined decisions cited by the appellant and revenue, including the Tribunal's decisions in Goa Antibiotics & Pharmaceuticals Ltd. and Glenmark Pharmaceuticals Ltd., and the Supreme Court's decision in Medley Pharmaceuticals Ltd., clarifying that valuation depends on the facts of each case.

In job work cases, the Court emphasized adherence to the Apex Court's formula in Ujagar Prints for valuation based on cost plus job charges and profit, reflecting transaction value principles.

Issue 5: Penalty Reduction and Demand Confirmation

The Commissioner (Appeals) had reduced the penalty from Rs. 4,21,311/- to Rs. 5,000/-, considering the circumstances. The Court did not interfere with this reduction, focusing primarily on the valuation issue.

Significant Holdings

"The transaction in question was between the assessee and the distributors. Between them, admittedly, price was charged by the assessee from the distributors. What ultimately distributors did with these goods is extraneous and could not be the relevant consideration to determine the valuation of excisable goods."

"The case would squarely be covered under the provisions of Section 4(1)(a) of the Act. In view thereof, the Central excise Rules would not apply in the instant case."

"In respect of physician samples being manufactured by job worker and sold to the principal manufacturer, valuation is to be done as per Ujagar Print's judgment of Apex Court."

"It is only on the ground that the goods were not actually sold by the distributors to the physicians, which was the ground on which it was contended that the case was not covered under Section 4(1)(a)."

"Where physician samples are manufactured on job work basis and cleared to the principal manufacturer on transaction value basis, the transaction value is the assessable value."

The Court established the core principle that the valuation of physician samples depends on the existence and nature of the sale transaction. If the manufacturer sells physician samples to distributors or principal manufacturers at a genuine price, the transaction value under Section 4(1)(a) governs. If the samples are distributed free by the manufacturer without sale, valuation under Rule 4 applies.

The final determinations were:

- The demand for additional duty based on Rule 4 valuation on physician samples manufactured on job work basis and cleared to principal manufacturers was rightly dropped.

- The demand for additional duty on physician samples manufactured and sold by the appellant to distributors was set aside, the transaction value being the correct assessable value.

- The penalty reduction by the Commissioner (Appeals) was maintained.

---